Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Abstract: Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a newly synthesized peptide, has been found to be safer than hydroquinone in reducing content of melanin, with efficacy up to more than 50 percent upon 16 weeks of twice daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and large molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation. We also tested the effects of chemical penetration enhancers and microneedles to deliver two peptides through skin. Enhanced human skin permeation was found using an in vitro skin permeation model. Moreover, we examined peptide retention of different formulations. Our data showed that palm-peptides in microneedle patch was the most effective.

Abstract: Two therapeutics, oligopeptides P5 and P14, which have proven to be selectively cytotoxic towards multiple melanoma cell lines in vitro. These oligopeptides offer an efficacious treatment for all types of pathogenic melanocytes and stages of melanoma, and a cost effective prophylactic to all individuals who are at high risk of developing skin cancer. In addition, these oligopeptides can be formulated into a sunscreen to serve as a prophylactic against any precancerous lesion or dysplastic nevi that might develop in high risk groups.

Abstract: A distance between a surface of a treatment head and tip opening of a skin treatment hand piece is adjustable. In an implementation, the distance is adjusted by moving the tip opening relative to the treatment head surface. Different distances may be used to treat different skin types, problems, and conditions. In an implementation, the hand piece includes a fluid delivery and a vacuum or suction mechanism to provide various therapeutic benefits to the skin.

Abstract: A microdermabrasion system offers a combination of other skin therapies in conjunction with microdermabrasion. In an implementation, the system applies light therapy, photodynamic therapy, radio frequency and microwave energy therapy, massage therapy, or combinations of these while exfoliating the skin.

Abstract: Embodiments relate to tyrosine inhibitors that exhibit immunosuppressive activity in human neonatal keratinocyte progenitors. Particular embodiments feature the immunosuppressive effects of a decapeptide and/or oxyresveratrol, as measured by two different methods: blockade of stimulated cell growth, and inhibition of cytotoxic killing.

Abstract: A microdermabrasion system offers a combination of other skin therapies in conjunction with microdermabrasion. In an implementation, the system applies light therapy, photodynamic therapy, radio frequency and microwave energy therapy, massage therapy, or combinations of these while exfoliating the skin.

Abstract: An abrasive tip is used to exfoliate skin and tissue through abrasive materials integrated in the tip. The tip also delivers fluid to the skin and vacuums the fluid and abraded tissue during treatment. Treated skin will look younger and healthier in appearance. In an implementation, the tip is replaceable and disposable.

Abstract: Isolated populations of mesenchymal stem cells (MSCs) are provided, including mammalian mesenchymal stem cells (MSCs) characterized by the lack of CD54 (CD54?) or low cell-surface CD54 (CD54low). Methods of in vitro cell differentiation and methods of treatment using said isolated populations are also provided.

Abstract: An abrasive tip is used to exfoliate skin and tissue through abrasive materials integrated in the tip. The tip also delivers fluid to the skin and vacuums the fluid and abraded tissue during treatment. Treated skin will look younger and healthier in appearance. In an implementation, the tip is replaceable and disposable.

Abstract: An abrasive tip is used to exfoliate skin and tissue through abrasive materials integrated in the tip. The tip also delivers fluid to the skin and vacuums the fluid and abraded tissue during treatment. Treated skin will look younger and healthier in appearance. In an implementation, the tip is replaceable and disposable.

Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Abstract: Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.

Abstract: Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.

Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Abstract: A distance between a surface of a treatment head and tip opening of a skin treatment hand piece is adjustable. In an implementation, the distance is adjusted by moving the tip opening relative to the treatment head surface. Different distances may be used to treat different skin types, problems, and conditions. In an implementation, the hand piece includes a fluid delivery and a vacuum or suction mechanism to provide various therapeutic benefits to the skin.

Abstract: A microdermabrasion system offers a combination of other skin therapies in conjunction with microdermabrasion. In an implementation, the system applies light therapy, photodynamic therapy, radio frequency and microwave energy therapy, massage therapy, or combinations of these while exfoliating the skin.

Abstract: Isolated populations of mesenchymal stem cells (MSCs) are provided, including mammalian mesenchymal stem cells (MSCs) characterized by the lack of CD54 (CD54?) or low cell-surface CD54 (CD54low). Methods of in vitro cell differentiation and methods of treatment using said isolated populations are also provided.

Abstract: Recent reports detail the pleiotropic roles sirtuins play in repressing premature aging, delaying cellular senescence, enhancing longevity, and ameliorating a wide range of aging disorders. Herein, we report our findings on the potent sirtuin activator, decapeptide-12, and compare its performance to the well documented oxyresveratrol. Treatment of human epidermal keratinocyte progenitors with 100 ?M decapeptide-12 increased transcription of SIRT1 by 141±11 percent relative to control cells, whereas levels of SIRT3, SIRT6, and SIRT7 were increased by 121±13 percent, 147±8 percent and 95.4±14 percent, respectively. Decapeptide-12 upregulated sirtuin transcription to similar levels as oxyresveratrol but with reduced cytotoxicity.